Cumberland announces partnership with Qureight

Cumberland (CPIX) Pharmaceuticals announced a partnership with Qureight, a Core Imaging Laboratory developing deep-learning image analytics, to enhance the outcome and output of data from Cumberland’s FIGHTING FIBROSIS clinical trial. The Phase II study is evaluating Cumberland’s ifetroban product candidate in patients with idiopathic pulmonary fibrosis, or IPF, the most common form of progressive fibrosing interstitial lung disease. This collaboration aims to address a critical unmet need for the estimated 2 million IPF patients worldwide, who currently have limited treatment options that can effectively halt disease progression. The partnership will utilize Qureight’s advanced, deep-learning image analytics tools for complex lung disease applications to provide deeper insights into treatment efficacy and disease progression in Cumberland’s IPF clinical program. Under this partnership, Qureight’s AI-driven analytics technologies will be used to quantify changes in multiple imaging biomarkers, using computed tomography data from FIGHTING FIBROSIS study patients. Qureight’s quantitative deep learning-based tools will precisely measure changes in the volume of patients’ fibrotic, vascular and airway lung compartments, allowing a more detailed investigation of ifetroban’s modulation of both lung structure and function.